# Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

> **NCT02248844** · — · COMPLETED · sponsor: **Allergan** · enrollment: 667 (actual)

## Conditions studied

- Lateral Canthal Lines
- Crow's Feet Lines

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT02248844
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-26
- **Primary completion:** 2017-08-14
- **Final completion:** 2017-08-14
- **Target enrollment:** 667 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248844, "Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02248844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*